RESEARCH
O&G Forum 2024; 34 – 2s: 750 - 755

BREAKING GROUND: LATEST INNOVATIONS AND THERAPIES IN OVARIAN CANCER TREATMENT

Ms. Subhasini.Y[1] , Dr. Sasikumar[2*], Dr. Jamunarani Srirangaramasamy[3], Dr. Balaji A[4], Dr. Desigamani,[5]
[1]PhD scholar, Meenakshi Academy of Higher Education and Research, KK Nagar Chennai, Tutor,
[2]Associate Professor, Department of Physiology, Tagore Medical College and Hospital, Chennai, India.600127.
[3]Professor & Head, Department of Pathology, Bhaarath Medical College Hospital, BIHER,, Selaiyur, Chennai 600073.
[4]Professor & Head, Department of Community Medicine, Arunai Medical College and Hospital, Tiruvannamalai, Tamilnadu, India.606603.
[5]Professor, Department of Biochemistry, Meenakshi Medical College and Hospital and Research Institute, Kancheepuram, Tamilnadu, India.631552.

***** simmamsasi@gmail.com Associate Professor, Department of Physiology, Tagore Medical College and Hospital, Chennai, India.600127.

Abstract

Ovarian cancer (OC) stands out as the most deadly among gynecologic tumors, characterized by high morbidity and low survival rates, particularly in advanced stages. Despite extensive research efforts, the lack of effective screening tools for early detection remains a significant challenge, contributing to the poor prognosis associated with OC. The current therapeutic management of OC involves a multidisciplinary approach, including debulking surgery, chemotherapy, and infrequently, radiotherapy. Immunomodulation has recently gained attention as a potential treatment avenue for OC. Relapse rates in OC are notably high, occurring approximately every two years, leading to intensified subsequent treatments. This recurrence poses challenges such as increased toxicity, chemotherapy resistance, and elevated financial burden, negatively impacting patients' quality of life. A promising strategy to address these challenges involves pre-sensitizing cancer cells with standard therapy, aiming to achieve optimal results with minimal dosage. This review extensively explores current research, biomarkers, treatment options, and ongoing clinical trials related to OC. The focus is on summarizing recent developments in translational and clinical research, with a systematic discussion of various strategies aimed at enhancing therapeutic responses in OC.

Key words: Ovarian cancer

INTRODUCTION:

Ovarian stromal cell tumors represent approximately 1% of all ovarian cancers. These tumors are more commonly diagnosed in women aged 50 and above, with more than half of cases occurring in this age group.[1] However, it's noteworthy that around 5% of ovarian stromal tumors manifest in young girls. This age distribution highlights the diversity in the occurrence of stromal tumors, affecting both older women and a small but notable percentage of younger individuals. Understanding these demographic patterns is crucial for tailored diagnosis and management approaches in different age groups. Epithelial ovarian cancer (EOC) is the most prevalent form of ovarian cancer. Unfortunately, individuals diagnosed with this lethal disease face a challenging prognosis, with a mere 45.6% 5-year survival rate.[2] This underscores the gravity of the situation and emphasizes the critical need for advancements in early detection and effective therapeutic interventions to improve outcomes for patients with EOC.[3, 4] The progression of OC is influenced by various factors, with genetic and epigenetic elements playing a crucial role. Among these, genetic factors, particularly mutations in the breast cancer genes BRCA1 and BRCA2, are deemed highly significant. Approximately 10%-15% of familial ovarian cancers is attributed to these mutations, underlining their substantial impact on the development and progression of the disease. Understanding these genetic and epigenetic influences is pivotal for advancing research and developing targeted interventions in the management of OC.[5] Oncogenes such as TP53, BRCA1 and BRCA2 play a pivotal role in the pathogenicity of OC by activating various signaling pathways. One notable consequence of this activation is the increased incidence of thrombosis associated with OC.[6] The malignancy's influence on coagulation pathways contributes to a higher rate of thrombotic events. This connection underscores the intricate relationship between oncogene-driven signaling pathways and the development of complications, highlighting the multifaceted nature of ovarian cancer's impact on physiological processes.[7]

1. CONTEXTUALIZING THE OVARIAN CANCER LANDSCAPE:

The current scenario of OC reveals a complex landscape marked by clinical challenges and an urgent need for advanced therapeutic solutions. This malignancy, particularly in its advanced stages, remains a formidable health concern. Challenges include the absence of robust early detection

methods, leading to diagnoses at later, less treatable stages. Multidisciplinary management involving surgery and chemotherapy is the norm; yet high recurrence rates pose ongoing hurdles. [8] The significant immunostimulatory agents, with their increasing use in oncology, align with the immunologic properties of OC, laying the groundwork for their integration into disease management strategies.[9] The significant immunostimulatory agents, with their increasing use in oncology, align with the immunologic properties of OC, laying the groundwork for their integration into disease management strategies. Immunomodulation is emerging as a promising avenue, but research is ongoing.[10]

Oncogene activation contributes to a higher incidence of thrombosis, adding complexity to the clinical picture. Furthermore, the prevalence of genetic and epigenetic factors, notably mutations in BRCA1 and BRCA2, significantly influences disease progression. The likelihood of an individual with a mutation developing OC seems to be impacted by several factors, including the specific location of the mutation within the BRCA gene, the existence of allelic variants in modifying genes, and the hormonal exposure experienced by the carrier. These multifaceted elements collectively contribute to the complex interplay that influences the cancer risk associated with BRCA gene mutations. [11]

2. HISTOPATHOLOGY OF OVARIAN CARCINOMA:

Pathophysiology of ovarian carcinoma involves a complex interplay of genetic, molecular, and environmental factors. Inherited mutations in the BRCA1 and BRCA2 genes are strongly associated with an increased risk of OC. Other genetic mutations, such as those involving TP53 and PTEN, may contribute to the development of OC.[12] Molecular Pathways: Dysfunctional DNA repair mechanisms, often associated with BRCA mutations, contribute to genomic instability and increased susceptibility to OC.[13] Aberrations in cell cycle regulation, including alterations in cyclins and cyclin-dependent kinases, promote uncontrolled cell proliferation.[14]

Factors such as nulliparity (never having given birth) and early onset of menstruation or late menopause may influence ovarian cancer risk.[15] Long-term use of hormone replacement therapy, particularly estrogen without progesterone, has been associated with an elevated risk.[16]Chronic inflammation in the ovarian epithelium may contribute to the initiation and progression of OC.[17]Ovarian carcinoma may evade immune surveillance by altering immune responses, allowing cancer cells to proliferate and evade destruction.[18] Ovarian tumors stimulate the growth of new blood vessels (angiogenesis) to supply nutrients and oxygen, facilitating tumor expansion.[19] Extracellular Matrix Interactions between cancer cells and the extracellular matrix play a role in tumor invasion and metastasis.[20]

Different histological subtypes of OC (serous, mucinous, endometrioid, clear cell, etc.) exhibit distinct molecular profiles and pathophysiological characteristics, influencing their behavior and response to treatment.[21] Understanding the pathophysiology of ovarian carcinoma is crucial for developing targeted therapies and improving early detection methods. Advances in molecular and genetic research continue to unveil the intricacies of ovarian cancer, paving the way for more personalized and effective treatment approaches.[22]

3. MULTIDISCIPLINARY STRATEGIES:

The multidisciplinary nature of OC management is addressed, acknowledging the combination of surgical interventions, chemotherapy, and, to a lesser extent, radiotherapy. The review recognizes the complexity of treating OC and the significance of a comprehensive approach. Multidisciplinary strategies for OC involve a collaborative and comprehensive approach to patient care, integrating various medical specialties to address the complex nature of the disease. Here are key components of multidisciplinary strategies in the management of ovarian cancer:

3.1 Gynecologic Oncology:

Surgical management is a cornerstone of OC treatment. Debulking surgery aims to remove as much of the tumor mass as possible, potentially increasing the effectiveness of subsequent therapies. Gynecologic oncologists specialize in the treatment of cancers affecting the female reproductive system, including OC.[23] They play a central role in surgical interventions and overall treatment planning. The field of gynecologic oncology has seen a progressively more assertive stance on cytoreductive surgery for OC, evolving from the era when Meigs highlighted the advantages of reducing tumor volume to Griffiths' groundbreaking paper, which presented the initial scientific proof of the inverse correlation between tumor volume and patient survival.[24] Over the years, the definition of "optimal cytoreduction" has evolved, shifting from a maximal residual disease of less than 2 cm to the present criteria of less than 1 cm residual disease, as stipulated by the Gynecologic Oncology Group (GOG). "Optimal debulking" is defined as the state achieved when there is either the complete absence of any residual disease or when no gross residual disease is evident following surgical intervention.[25]

3.2 Medical Oncology:

Medical oncologists administer systemic treatments, such as chemotherapy, to target cancer cells throughout the body. They contribute to treatment planning and monitor patients during and after chemotherapy. In 2018, van Driel et al.[26] conducted a multicenter, open-label, Phase 3 randomized controlled trial. The study involved 245 patients who exhibited at least stable disease after three cycles of carboplatin and paclitaxel. These patients underwent interval cytoreductive surgery, and the trial compared outcomes between those who received hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin and those who did not. The authors reached the conclusion that for individuals diagnosed with Stage III epithelial OC, the incorporation of hyperthermic intraperitoneal chemotherapy (HIPEC) into interval cytoreductive surgery led to prolonged recurrence-free survival and overall survival compared to surgery alone. Importantly, this combined approach did not result in elevated rates of adverse effects.[26]

3.3 Radiation Oncology:

Radiation oncologists may be involved in cases where radiation therapy is deemed beneficial. This may be utilized in specific situations, such as after surgery or for palliative care. The line between curative and palliative objectives becomes unclear for many cancer patients, necessitating treatment decisions that are guided by various patient-related factors.[27]

3.4 Pathology and Molecular Diagnostics:

Pathologists analyze tissue samples to confirm the diagnosis and determine the tumor's characteristics. Molecular

pathology plays a crucial role in pathology by complementing traditional morphological tools. It contributes to achieving a comprehensive and accurate diagnosis, ensuring an integrated understanding of the disease. This approach is especially valuable for assessing prognosis and predicting the response to therapy, with a particular emphasis on cancer cases.[28] Over the past decade, there has been a substantial increase in the number of tumor-specific molecular aberrations that can be targeted by drugs. This growth has led to significant survival benefits through therapies that are matched to specific biomarkers, particularly in various types of cancer. Molecular diagnostics help identify specific genetic and molecular features, guiding treatment decisions. [4]

The present and prospective uses of liquid biopsies involve assessing blood-based biomarkers, including circulating tumor cells and circulating nucleic acids. Additionally, insights gained from the constraints of genotype-derived therapies offer valuable lessons for expanding precision medicine beyond genomics. Mutation analysis has become a standard practice in the diagnosis of hereditary cancer syndromes, commonly employed for accurate identification and characterization.([28, 29)] Multidisciplinary collaboration ensures that patients receive holistic and individualized care, considering the various facets of their diagnosis, treatment, and overall well-being. This approach optimizes the management of OC, improving outcomes and enhancing the patient's quality of life.

4. CHALLENGES IN EARLY DETECTION OF OVARIAN CANCERS

The early detection of ovarian cancer poses significant challenges primarily due to several factors such as non-specific symptoms and asymptomatic nature of disease. OC often develops without causing noticeable symptoms in its early stages.[30] This asymptomatic nature makes it difficult to detect the disease at a point where it is more treatable. When symptoms do arise, they are often non-specific and can be attributed to other common conditions. Symptoms such as bloating, abdominal discomfort, and changes in appetite may not immediately raise concerns for ovarian cancer.[31]

Anatomical location and absence of early warning signs may be the upcoming challenges in the OC. The ovaries are situated deep within the pelvic cavity, making them challenging to access for routine examinations. This contributes to the difficulty in detecting abnormalities or tumors at an early stage. OC tends to progress silently without producing early warning signs that could prompt individuals to seek medical attention. By the time symptoms become noticeable, the cancer may have reached an advanced stage.

OC risk factors encompass a combination of genetic, hormonal, and environmental factors.[32] Understanding these risk factors is essential for early detection and preventive measures. While there are known risk factors, such as a family history of ovarian or breast cancer, these alone are not sufficient to identify individuals at an early stage. Moreover, many cases occur in individuals without clear risk factors. A strong familial history of OC increases the risk. Individuals with first-degree relatives (mother, sister, daughter) diagnosed with ovarian cancer are at an elevated risk.

OC has a relatively low incidence compared to some other cancers, making it less of a focus for routine screening efforts. However, its high mortality rate emphasizes the importance of early detection and intervention.[33]

Unlike some other cancers, there are no highly sensitive and specific screening tests for OC. Mammography, for example, is a widely used screening tool for breast cancer, but there is no equivalent for OC that is as effective

OC exhibits significant genetic and molecular heterogeneity, meaning that different subtypes of the cancer may present with distinct characteristics. This variability complicates the development of a universal early detection method.

Efforts are ongoing to address these challenges, with research focusing on identifying specific biomarkers, improving imaging technologies, and understanding the genetic basis of ovarian cancer. Early detection remains a critical area for advancing outcomes in ovarian cancer treatment.

5. ANALYSIS OF CLINICAL TRIALS IN OVARIAN CANCERS

Clinical trials in OC play a pivotal role in advancing our understanding of the disease and improving treatment options. Several key aspects characterize ongoing and recent clinical trials in OC. Trials often focus on testing innovative therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments.[34] These aim to enhance treatment efficacy while minimizing side effects. Testing combination therapies is a common theme in ovarian cancer trials. These combinations may involve traditional chemotherapy, targeted agents, and immunotherapies, aiming to improve overall treatment outcomes.[(7, 30)]

The proposition suggests that vaccination utilizing specific anti-idiotypic antibodies could enhance the survival benefit for patients with recurrent ovarian cancer (OC) with minimal side effects. Consequently, the integration of noninvasive immunotherapy alongside combination chemotherapy emerges as a potential therapeutic strategy, aiming to improve overall survival in individuals with ovarian cancer. [35] This approach signifies a concerted effort to explore innovative and less invasive interventions for enhanced treatment outcomes in the context of recurrent OC.[7] While the CA125 antigen exhibits limited sensitivity and specificity, it is closely associated with epithelial ovarian carcinoma. Despite its constraints, the diagnostic performance of this biomarker has proven to be valuable in primary care settings, particularly among women aged 50 and older. The CA125 antigen is commonly utilized as a tool for identifying potential cases of OC, emphasizing its role in clinical assessment and decision-making, especially in older female populations.[36] With an increasing emphasis on precision medicine, clinical trials explore therapies tailored to specific molecular subtypes of OC. This involves identifying and targeting genetic mutations or alterations unique to individual patients. Tumors, even within the same type, can arise from various underlying genetic causes and may exhibit distinct protein expressions from one patient to another. This inherent variability in cancer forms the foundation of the expanding field of precision and personalized medicine (PPM). Numerous ongoing initiatives aim to collect PPM data, seeking to delineate the molecular distinctions among tumors. This approach recognizes the unique genetic and molecular profiles of individual tumors, paving the way for tailored and targeted therapeutic strategies in cancer treatment.[37]

Some trials are dedicated to improving early detection methods and screening tools for OC. This is crucial for identifying the disease at a more treatable stage, as OC is often diagnosed in advanced stages. The team's focus on alterations in DNA methylation, which deviate from the normal patterns, stems from the understanding that these changes occur early in

the formation of cancer. Consequently, the team embarked on developing an assay that leverages these changes for the detection of OC in plasma. However, the development of a marker panel posed challenges. One significant hurdle was the identification of patients with early-stage ovarian cancer for study inclusion, given that this cancer is typically not detected until stage 3 or 4 in approximately 75% of patients. This intrinsic characteristic of delayed detection presented a unique obstacle in the pursuit of effective diagnostic methods for early-stage ovarian cancer.[38] Beyond treatment efficacy, clinical trials assess the impact of interventions on patients' quality of life and overall well-being. This includes exploring supportive care measures to manage treatment-related side effects.

Understanding and overcoming drug resistance is a significant focus in OC trials. Research aims to identify mechanisms of resistance and develop strategies to enhance treatment effectiveness. Trials investigate the benefits of adjuvant and neoadjuvant therapies in different stages of OC. This includes evaluating the timing of treatments and their impact on surgical outcomes. Participation in clinical trials is crucial for advancing ovarian cancer research and improving outcomes for patients. These trials contribute valuable data that shapes the future OC treatment, leading to more effective and personalized approaches.

6. FUTURE DIRECTIONS AND RESEARCH AVENUES:

The **future directions and research avenues** for OC encompass a range of promising areas aimed at improving early detection, refining treatment strategies, and enhancing overall patient outcomes. Some key areas of focus include:

6.1 Biomarker Discovery:

Identifying and validating novel biomarkers for early detection and accurate diagnosis of OC is a crucial avenue of research. Biomarkers can enhance screening methods and contribute to a more personalized approach to treatment.[39]

6.2 Liquid Biopsies:

Exploring the potential of liquid biopsies, which involve analyzing blood or other bodily fluids for circulating tumor cells, cell-free DNA, and other biomolecules, as non-invasive methods for early detection, monitoring treatment response, and detecting recurrence.

6.3 Genomic and Molecular Profiling:

Advancing genomic and molecular profiling techniques have to better understand the genetic heterogeneity of OC. This includes identifying key driver mutations and molecular pathways, which could inform targeted therapies and personalized treatment plans.[40]

6.4 Immunotherapy:

Investigating the role of immunotherapy in OC treatment. Understanding the immune landscape of ovarian tumors and developing immunotherapeutic strategies, such as immune checkpoint inhibitors, to enhance the body's ability to fight cancer.[41]

6.5 Early Intervention Strategies:

Developing strategies for early intervention in high-risk populations, including those with a family history of OC or carrying specific genetic mutations (e.g., BRCA1/2). Exploring prophylactic measures and surveillance protocols to detect cancer at an earlier, more treatable stage.

6.6. Drug Development and Targeted Therapies:

Continuously identifying and developing new drugs and targeted therapies tailored to specific molecular subtypes of OC. Investigating combination therapies and overcoming resistance mechanisms to enhance treatment efficacy.[42,43]

6.7 Artificial Intelligence and Imaging Technologies:

Harnessing the power of artificial intelligence and improving imaging technologies for more accurate and efficient diagnosis. Enhancing the sensitivity and specificity of imaging modalities, such as MRI and ultrasound, for early detection and monitoring of OC.[44 45]

6.8 Patient-Centered Research:

Emphasizing patient-centered research to understand the psychosocial impact of OC and improving supportive care measures. Exploring survivorship issues, quality of life, and addressing the unique challenges faced by OC patients. By pursuing these research avenues, the goal is to transform the landscape of OC management, offering more effective and personalized approaches that ultimately improve patient outcomes and quality of life.[46]

7. SUMMARY AND CONCLUSIONS

In summary, the current therapeutic approach to OC encompasses a multidisciplinary strategy involving debulking surgery, chemotherapy, and occasional radiotherapy. Immunomodulation has emerged as a promising avenue for OC treatment. However, the high recurrence rates, occurring roughly every two years, present significant challenges. Subsequent treatments following relapse are often intensified, resulting in increased toxicity, resistance to chemotherapy, and a heightened financial burden. These challenges collectively contribute to a negative impact on the quality of life for patients with ovarian cancer. In conclusion, while advancements have been made in the therapeutic landscape, addressing the complexities of relapse and its associated consequences remains a critical focus for improving outcomes and enhancing the overall well-being of individuals with ovarian cancer.

REFERENCES:

1. *American Cancer Society. Cancer Facts & Figures 2023. Atlanta, Ga: American Cancer Society; 2023.*
2. *Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-454.*
3. *Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;(1):Cd005340.*
4. *Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415-428.*
5. *Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med. 2005;3:25 Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metas. 2009;26(7):653-661.*
6. *Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019 Nov;8(16):7018-7031. doi: 10.1002/cam4.2560. Epub 2019 Sep 27.*
7. *Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. Onco Targets Ther. 2020 Jun 26;13:6109-6129. doi: 10.2147/OTT.S205950.*

8. *Demircan NC, Boussios S, Tasci T, Öztürk MA. Current and future immunotherapy approaches in ovarian cancer. Annals of Translational Medicine. 2020 Dec;8(24).*
9. *Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis. 2005 Oct 1;26(10):1651-6.*
10. *Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. Translational cancer research. 2016 Dec;5(6):650.*
11. *Gorodetska I, Kozeretska I, Dubrovska A. BRCA genes: the role in genome stability, cancer stemness and therapy resistance. Journal of Cancer. 2019;10(9):2109.*
12. *Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. International journal of molecular sciences. 2020 Mar 13;21(6):1960.*
13. *Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health. 2019 Apr 30:287-99.*
14. *Valdes, A. and Bajaj, T., 2019. Estrogen therapy.*
15. *Aceto GM, Cheon DJ. Molecular Physiopathology of Epithelial Ovarian Cancer: Role of Inflammation. Frontiers in Oncology.;13:1357842.*
16. *Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Frontiers in Pharmacology. 2022 May 24;13:868695.*
17. *Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vascular health and risk management. 2006 Sep 30;2(3):213-9.*
18. *Elgundi Z, Papanicolaou M, Major G, Cox TR, Melrose J, Whitelock JM, Farrugia BL. Cancer metastasis: the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Frontiers in oncology. 2020 Jan 17;9:1482.*
19. *Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nature reviews Disease primers. 2016 Aug 25;2(1):1-22.*
20. *Chilimoniuk Z, Rocka A, Stefaniak M, Tomczyk Ż, Jasielska F, Madras D, Filip A. Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review. Future Oncology. 2022 Apr;18(13):1627-50.*
21. *Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460-1466.*
22. *Arora V, Somashekhar SP. Essential surgical skills for a gynecologic oncologist. International Journal of Gynecology & Obstetrics. 2018 Oct;143:118-30.*
23. *Angarita AM, Stone R, Temkin SM, Levinson K, Fader AN, Tanner EJ. The use of "optimal cytoreduction" nomenclature in ovarian cancer literature: Can we move toward a more optimal classification system? Int J Gynecol Cancer. 2016; 26: 1421–1427.*
24. *Stuart GCE, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2011; 21: 750–755.*
25. *van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378: 230–240.*
26. *Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. Journal of Clinical Oncology. 2014 Sep 9;32(26):2913.*
27. *Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H, European Society of Pathology (ESP). The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Archiv. 2020 Apr;476:491-7.*
28. *Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020 Dec;12(1):1-9.*
29. *Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. Frontiers in molecular biosciences. 2018 Aug 27;5:76.*
30. *Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170-177.*
31. *van Nagell JR Jr., DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109(9):1887-1896.*
32. *Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H, European Society of Pathology (ESP). The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Archiv. 2020 Apr;476:491-7.*
33. *Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response. Signal Transduction and Targeted Therapy. 2022 Sep 19;7(1):331.*
34. *Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):273s-309s.*
35. *Funston G., Hamilton W., Abel G., Crosbie E.J., Rous B., Walter F.M. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020;17:e1003295. doi: 10.1371/journal.pmed.1003295*
36. *Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018 Sep-Dec;6(3-4):79-100. doi: 10.1142/S2339547818300020. Epub 2019 Jan 11.*
37. *Marinelli LM. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecologic Oncology. 2022;165:568.*
38. *Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer. 1998;78(11):1479-1487.*
39. *Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP. Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific*

lectin SubB2M. Biochem Biophys Res Commun. 2018;507(1–4):173-177.

40. *Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217-1228.*
41. *McCloskey CW, Rodriguez GM, Galpin K, Vanderhyden BC. Ovarian cancer immunotherapy: preclinical models and emerging therapeutics. Cancers. 2018;10(8):244.*
42. *Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer. 1998;78(11):1479-1487*
43. *Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31-47.*
44. *Ruytenberg T, Verbist BM, Vonk-Van Oosten J, Astreinidou E, Sjögren EV, Webb AG. Improvements in high resolution laryngeal magnetic resonance imaging for preoperative transoral laser microsurgery and radiotherapy considerations in early lesions. Front Oncol. 2018;8:216*
45. *Zheng Q, Yang L, Zeng B, et al. Artificial intelligence performance in detecting tumor metastasis from medical radiology imaging: a systematic review and meta-analysis. EClinicalMedicine. 2020;31*
46. *Pozzar RA, Xiong N, Hong F, Wright AA, Goff BA, Underhill-Blazey ML, Tulsky JA, Hammer MJ, Berry DL. How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study. Gynecologic Oncology. 2022 Nov 1;167(2):261-8.*
47. *Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170-177.*
48. *Grossman DC, Curry SJ, Owens DK, et al. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(6):588-594.*
49. *Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217-1228.*